Effectiveness and Cost-Effectiveness of Smoking Cessation in COPD Patients
Author Information
Author(s): Atsou Kokuvi, Chouaid Christos, Hejblum Gilles
Primary Institution: INSERM, U707, Paris, France
Hypothesis
What is the effectiveness and cost-effectiveness of smoking cessation for patients with chronic obstructive pulmonary disease (COPD)?
Conclusion
Smoking cessation in COPD patients leads to increased life expectancy, improved quality of life, and reduced disease-related costs.
Supporting Evidence
- Smoking cessation at cohort initialization leads to a mean gain of 1.27 life-years and 0.68 QALY.
- The cost savings from smoking cessation amount to £1824 per patient over their remaining lifetime.
- The incremental cost-effectiveness ratio (ICER) for smoking cessation is -2686 £/QALY.
Takeaway
If you have COPD and you stop smoking, you can live longer and feel better, and it will also save money on healthcare.
Methodology
A multi-state Markov model was developed to simulate cohorts of COPD patients comparing those who quit smoking to those who continued.
Potential Biases
Potential biases in the model due to assumptions about smoking cessation rates and costs.
Limitations
The model's parameters were based on data not specific to the English population, and uncertainties exist regarding transition rates and costs.
Participant Demographics
Cohorts included English COPD patients aged 40 to 89 years, with varying severity stages.
Statistical Information
P-Value
-2686
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website